Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sanara MedTech Inc.SMTI · Entity 5880 | Controller | March 22, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sanara MedTech Inc.
Report date March 22, 2026 · Filed May 05, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,967 |
Reported balance
After 2026-03-22 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-22 · Grant · Acquired 2,804 · Balance 4,967 F1: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date. F2: The original Form 4, filed on March 23, 2026, is being amended and restated in its entirety to reduce the number of shares of common stock of the Issuer reported as being beneficially owned by the reporting person. The original Form 4 mistakenly indicated that the reporting person held 5,067 shares of common stock, when in fact, as reported in this amendment, the reporting person held 4,967 shares of common stock following the reported transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date.
F2: The original Form 4, filed on March 23, 2026, is being amended and restated in its entirety to reduce the number of shares of common stock of the Issuer reported as being beneficially owned by the reporting person. The original Form 4 mistakenly indicated that the reporting person held 5,067 shares of common stock, when in fact, as reported in this amendment, the reporting person held 4,967 shares of common stock following the reported transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 22, 2026 Filed Mar 23, 2026 20:35 UTC | Sanara MedTech Inc. SMTI · Entity 5880 | GrantCommon Stock | 2,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-012183 · ownership.xml · nonDerivative · entry 1 Mackey Ashley M · CIK 0002084457 · Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,067 F1 · shares: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date. F1 · price: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date. Read SEC document |
| March 22, 2026 Filed May 5, 2026 20:05 UTC Amendment | Sanara MedTech Inc. SMTI · Entity 5880 | GrantCommon Stock | 2,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-021296 · ownership.xml · nonDerivative · entry 1 Mackey Ashley M · CIK 0002084457 · Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,967 F1 · shares: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date. F1 · price: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date. F1 · balance_after: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date. F2 · balance_after: The original Form 4, filed on March 23, 2026, is being amended and restated in its entirety to reduce the number of shares of common stock of the Issuer reported as being beneficially owned by the reporting person. The original Form 4 mistakenly indicated that the reporting person held 5,067 shares of common stock, when in fact, as reported in this amendment, the reporting person held 4,967 shares of common stock following the reported transaction. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:18 UTC | Sanara MedTech Inc. SMTI · Entity 5880 | Tax withholdingCommon Stock | 149 | $19.90 | $2,965.10 |
DisclosureSEC source: 0001493152-26-008335 · ownership.xml · nonDerivative · entry 1 Mackey Ashley M · CIK 0002084457 · Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,263 F1 · shares: Represents shares of common stock of Sanara MedTech Inc. (the "Issuer") withheld by the Issuer to satisfy tax withholding obligations in connection with the annual vesting of 502 shares of restricted stock previously granted to the reporting person. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market. F1 · price: Represents shares of common stock of Sanara MedTech Inc. (the "Issuer") withheld by the Issuer to satisfy tax withholding obligations in connection with the annual vesting of 502 shares of restricted stock previously granted to the reporting person. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.